Research programme: endothelin B receptor antagonists - ENB TherapeuticsAlternative Names: ENB 001; ENB 002; ETBR blocker - ENB Therapeutics
Latest Information Update: 01 Oct 2016
At a glance
- Originator ENB Therapeutics
- Class Small molecules
- Mechanism of Action Endothelin B receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Glioblastoma; Head and neck cancer; Malignant melanoma